GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Hunan Hansen Pharmaceutical Co Ltd (SZSE:002412) » Definitions » Debt-to-Equity

Hunan Hansen Pharmaceutical Co (SZSE:002412) Debt-to-Equity : 0.04 (As of Mar. 2025)


View and export this data going back to 2011. Start your Free Trial

What is Hunan Hansen Pharmaceutical Co Debt-to-Equity?

Hunan Hansen Pharmaceutical Co's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2025 was ¥83 Mil. Hunan Hansen Pharmaceutical Co's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2025 was ¥0 Mil. Hunan Hansen Pharmaceutical Co's Total Stockholders Equity for the quarter that ended in Mar. 2025 was ¥2,193 Mil. Hunan Hansen Pharmaceutical Co's debt to equity for the quarter that ended in Mar. 2025 was 0.04.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Hunan Hansen Pharmaceutical Co's Debt-to-Equity or its related term are showing as below:

SZSE:002412' s Debt-to-Equity Range Over the Past 10 Years
Min: 0.01   Med: 0.09   Max: 0.33
Current: 0.04

During the past 13 years, the highest Debt-to-Equity Ratio of Hunan Hansen Pharmaceutical Co was 0.33. The lowest was 0.01. And the median was 0.09.

SZSE:002412's Debt-to-Equity is ranked better than
84.96% of 818 companies
in the Drug Manufacturers industry
Industry Median: 0.27 vs SZSE:002412: 0.04

Hunan Hansen Pharmaceutical Co Debt-to-Equity Historical Data

The historical data trend for Hunan Hansen Pharmaceutical Co's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Hunan Hansen Pharmaceutical Co Debt-to-Equity Chart

Hunan Hansen Pharmaceutical Co Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Debt-to-Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.11 0.08 0.06 0.05 0.04

Hunan Hansen Pharmaceutical Co Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Debt-to-Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.05 0.04 0.04 0.04 0.04

Competitive Comparison of Hunan Hansen Pharmaceutical Co's Debt-to-Equity

For the Drug Manufacturers - Specialty & Generic subindustry, Hunan Hansen Pharmaceutical Co's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Hunan Hansen Pharmaceutical Co's Debt-to-Equity Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Hunan Hansen Pharmaceutical Co's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Hunan Hansen Pharmaceutical Co's Debt-to-Equity falls into.


;
;

Hunan Hansen Pharmaceutical Co Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Hunan Hansen Pharmaceutical Co's Debt to Equity Ratio for the fiscal year that ended in Dec. 2024 is calculated as

Hunan Hansen Pharmaceutical Co's Debt to Equity Ratio for the quarter that ended in Mar. 2025 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Hunan Hansen Pharmaceutical Co  (SZSE:002412) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.


Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.


Hunan Hansen Pharmaceutical Co Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Hunan Hansen Pharmaceutical Co's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.


Hunan Hansen Pharmaceutical Co Business Description

Traded in Other Exchanges
N/A
Address
Silver City Road, Long Ridge Industrial Park, Heshan District, Yiyang City, CHN, 413000
Hunan Hansen Pharmaceutical Co Ltd is producing Chinese and Western medicines. Its main dosage forms include large-volume injections, small-volume injections, oral liquids, tablets, hard capsules, granules, syrups, ointments, tinctures, and pills. The company's main products are Si Mo Tang Oral Liquid, Shuanquan Capsule, Ginkgo Biloba Capsule and Tianma Xingnao Capsule.
Executives
Luo Yong Qing Directors, executives
Liu Zheng Qing Directors, executives
Liu Ling An Director
Fu Jian Jun Executives
Liu Na Xin Independent director
Liu Hou Yao Directors, Directors, and Executives
He San Xing Directors, executives

Hunan Hansen Pharmaceutical Co Headlines

No Headlines